On the one hand, GSTM3 influences the malignant metabolic pattern in pancreatic cancer, alleviates aggressiveness in renal cell carcinoma, and reverses radioresistance in hepatocellular carcinoma to suppress tumour malignancy [25–27]. This evidence concerns the gene GSTM3 and neoplasm.